Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.34 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.34 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.34 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.34 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.34 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.34 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.34 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.34 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.34 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.34 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442860 | 0.85 | HCAR2 (0.58) | HCAR2CCNE1CDK2CDK5PSMB10 | |
| SCHEMBL27858708 | 0.79 | HCAR2 (0.72) | HCAR2CDC7DBF4RAB9ASMN1; SMN2 | |
| SCHEMBL27395757 | 0.78 | ALDH1A1 (0.38) | HCAR2CCNE1CDK2CDK5LIMK1 | |
| SCHEMBL186167 | 0.77 | — | — | |
| SCHEMBL4781387 | 0.77 | — | — | |
| SCHEMBL27315807 | 0.76 | BTK (0.37) | HCAR2CCNE1CDK2CDK5RAB9A | |
| SCHEMBL1435803 | 0.75 | — | — | |
| SCHEMBL328096 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL9653796 | 0.75 | HCAR2 (0.96) | HCAR2RAB9ASMN1; SMN2GAAMAPT | |
| SCHEMBL17248050 | 0.74 | MAPK14 (0.50) | CCNE1CDK2CDK5RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2019075252-A1 | PEPTIDOMIMETIC PROTEASOME INHIBITORS | CORNELL UNIVERSITY (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | HCAR2 1220/4885CCNE1 1476/4885CDK2 96/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | HCAR2 4578/4885CCNE1 1128/4885CDK2 1536/4885 |
| US-11026930-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HCAR2 3659/4885CCNE1 1903/4885CDK2 1140/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HCAR2 1220/4885CCNE1 1476/4885CDK2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.